1
|
Kasai S, Sato E, Sakaguchi C, Sasaki Y. Tumor Lysis Syndrome in a Patient with BRAF V600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib. Intern Med 2024:2925-23. [PMID: 38631859 DOI: 10.2169/internalmedicine.2925-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2024] Open
Abstract
Tumor lysis syndrome (TLS) is a fatal complication associated with chemotherapy. We herein report a case of TLS in a 73-year-old woman with metastatic BRAFV600E mutated colon cancer after she received combined treatment with cetuximab and encorafenib. The serum uric acid, urea nitrogen, and creatinine levels were elevated on day four of the first cycle. The fibrin degradation product (FDP) and D-dimer levels were also high. Diuresis and rasburicase were initiated for TLS, and the laboratory data all normalized on day 8. Thus, the possibility of TLS being induced by targeted drugs in patients with solid tumors, including colorectal cancer, must not be overlooked.
Collapse
Affiliation(s)
- Shunsuke Kasai
- Department of Medical Oncology, Rakuwakai-Otowa Hospital, Japan
| | - Etsuko Sato
- Department of Medical Oncology, Rakuwakai-Otowa Hospital, Japan
| | | | | |
Collapse
|
2
|
Yamauchi R, Fujisawa M, Koyanagi S, Muramatsu A, Kobayashi T, Wada Y, Akama K, Tanaka M, Kurashige H, Sato A, Horiuchi H, Mukai T, Yamamoto Y, Sasaki Y. Formate-producing capacity provided by reducing ability of Streptococcus thermophilus nicotinamide adenine dinucleotide oxidase determines yogurt acidification rate. J Dairy Sci 2023; 106:6710-6722. [PMID: 37211485 DOI: 10.3168/jds.2023-23245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 04/19/2023] [Indexed: 05/23/2023]
Abstract
Yogurt is made by fermenting milk with 2 lactic acid bacteria, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus thermophilus. To comprehensively understand the protocooperation mechanism between S. thermophilus and L. bulgaricus in yogurt fermentation, we examined 24 combinations of cocultures comprising 7 fast- or slow-acidifying S. thermophilus strains with 6 fast- or slow-acidifying L. bulgaricus strains. Furthermore, 3 NADH oxidase (Nox)-deficient mutants (Δnox) and one pyruvate formate-lyase deficient mutant (ΔpflB) of S. thermophilus were used to evaluate the factor that determines the acidification rate of S. thermophilus. The results revealed that the acidification rate of S. thermophilus monoculture determined the yogurt fermentation rates, despite the coexistence of L. bulgaricus, whose acidification rate was either fast or slow. Significant correlation was found between the acidification rate of S. thermophilus monoculture and the amount of formate production. Result using ΔpflB showed that the formate was indispensable for the acidification of S. thermophilus. Moreover, results of the Δnox experiments revealed that formate production required Nox activity, which not only regulated dissolved oxygen, but also the redox potential. The Nox provided the large decrease in redox potential required by pyruvate formate-lyase to produce formate. A highly significant correlation was found between formate accumulation and Nox activity in S. thermophilus. In conclusion, the formate production ability provided by the action of Nox activity determines the acidification rate of S. thermophilus, and consequently, regulates yogurt coculture fermentation.
Collapse
Affiliation(s)
- R Yamauchi
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - M Fujisawa
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - S Koyanagi
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - A Muramatsu
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - T Kobayashi
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - Y Wada
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - K Akama
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - M Tanaka
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| | - H Kurashige
- Department of Animal Science, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23, Towada, Aomori 034-8628, Japan
| | - A Sato
- Department of Animal Science, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23, Towada, Aomori 034-8628, Japan
| | - H Horiuchi
- Food Science and Technology Research Laboratories, R&D Division, Meiji Co. Ltd., 1-29-1 Nanakuni, Hachioji, Tokyo 192-0919, Japan
| | - T Mukai
- Department of Animal Science, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23, Towada, Aomori 034-8628, Japan
| | - Y Yamamoto
- Department of Animal Science, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23, Towada, Aomori 034-8628, Japan
| | - Y Sasaki
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan.
| |
Collapse
|
3
|
Nio Y, Ishida H, Matsumoto N, Kusumoto S, Kubota Y, Tsunoda T, Sasaki Y, Fujita KI. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC Pulm Med 2022; 22:454. [PMID: 36451169 PMCID: PMC9710131 DOI: 10.1186/s12890-022-02249-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 11/16/2022] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been examined, we prospectively assessed the pharmacokinetics of gefitinib in patients with epidermal growth factor receptor gene-mutated advanced NSCLC who were 75 years or older. METHODS Gefitinib was orally administered once daily at a dose of 250 mg. The concentrations of gefitinib and its major metabolite O-desmethyl gefitinib in plasma were measured by high-performance liquid chromatography. The area under the plasma concentration-time curve from time 0 to 48 h (AUC0-48) was calculated. Polymorphisms in CYP3A5, CYP2D6, ABCG2, ABCB1, and OATP1B1 were analyzed by direct sequencing. RESULTS Eighteen patients with a median age of 80.5 years (range, 75-89) with adequate liver and kidney functions were examined. AUC0-48 values of gefitinib and O-desmethyl gefitinib in this population were 9.49 ± 3.5 and 10.6 ± 14 µM h, respectively. Compared to the gefitinib pharmacokinetics observed in a previous phase I study in Japan, systemic exposure to gefitinib in elderly patients was slightly higher than that in younger patients. Three patients experienced grade 3 diarrhea, increases in alanine aminotransferase, and aspartate aminotransferase levels 30 days after starting gefitinib treatment. The CYP2D6 genotype was associated with CYP2D6-mediated metabolism of gefitinib to O-desmethyl gefitinib. CONCLUSIONS We demonstrated for the first time the systemic exposure to gefitinib in elderly patients with NSCLC. TRIAL REGISTRATION The study was registered with the University Hospital Medical Information Network-Clinical Trials Registry Japan (UMIN000026409) on November 8, 2013.
Collapse
Affiliation(s)
- Yuta Nio
- grid.410714.70000 0000 8864 3422Department of Hospital Pharmaceutics, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Hiroo Ishida
- grid.410714.70000 0000 8864 3422Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Natsumi Matsumoto
- grid.410714.70000 0000 8864 3422Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Sojiro Kusumoto
- grid.410714.70000 0000 8864 3422Division of Respirology and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Yutaro Kubota
- grid.410714.70000 0000 8864 3422Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Takuya Tsunoda
- grid.410714.70000 0000 8864 3422Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Yasutsuna Sasaki
- grid.410714.70000 0000 8864 3422Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Ken-ichi Fujita
- grid.410714.70000 0000 8864 3422Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| |
Collapse
|
4
|
Sasaki Y, Abe Y, Nishise S, Ueno Y. Reply: Serum pancreatic amylase and colorectal adenoma: From clinical research to practice. J Gastroenterol Hepatol 2022; 37:2189-2190. [PMID: 36068019 DOI: 10.1111/jgh.15993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Accepted: 09/03/2022] [Indexed: 12/09/2022]
Affiliation(s)
- Y Sasaki
- Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan
| | - Y Abe
- Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan.,Division of Endoscopy, Yamagata University Hospital, Yamagata, Japan
| | - S Nishise
- Tohoku Central Hospital, Yamagata, Japan
| | - Y Ueno
- Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan
| |
Collapse
|
5
|
Sano M, Toyota T, Morimoto T, Okada T, Sasaki Y, Taniguchi T, Kim K, Kobori A, Ehara N, Kinoshita M, Doi A, Tomii K, Kihara Y, Furukawa Y. Prediction of clinical outcomes in patients with coronavirus disease 2019 using high-sensitive troponin I and N-terminal pro-B-type natriuretic peptide. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Several comorbidities, including cardiovascular diseases or myocardial injury, are reported to be associated with poor prognosis in patients with Coronavirus disease 2019 (COVID-19). However, detailed prognostic analysis of myocardial injury by various biomarkers in COVID-19 patients is limited.
Purpose
This study aims to explore the prognostic values of high-sensitive Troponin I (hsTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for COVID-19 patients using Japanese real-world data.
Methods
The COVID-MI study is a retrospective cohort study that enrolls consecutive laboratory-confirmed COVID-19 patients admitted to the hospital from July 2020 to September 2021. We collected clinical data, including cardiac biomarker values, by chart review. If the prespecified biomarkers in concern were not available, we measured them using the institutional serum blood bank, which enrolled patients prospectively from July 2020. Patients with available biomarkers were analyzed according to the values of hsTnI or NT-proBNP, using the clinically relevant thresholds (hsTnI: 5 ng/L and 99th percentile of the upper reference limit [99%ile URL], and NT-proBNP: 125 pg/mL and 900 pg/mL). The primary outcome measure was all-cause death. Secondary outcome measures included acute respiratory distress syndrome, myocardial infarction, myocarditis/pericarditis, venous thromboembolism, cerebral infarction, and bleeding events.
Results
We enrolled 917 patients with COVID-19 confirmed by viral nucleic acid amplification test. The mean age was 61 years, and 591 patients (64%) were men. On admission, the number of patients classified as severe or critical COVID-19 was 515 (56%) and 85 (8.7%), respectively. Among the 544 patients with hsTnI values, 365 (67%) patients had elevated hsTnI of ≥5 ng/L, and 134 patients (25%) had TnI of ≥99%ile URL. Besides, among 546 patients with NT-proBNP values, 295 patients (54%) had elevated NT-pro-BNP of ≥125 pg/mL, and 93 patients (17%) had NT-proBNP of ≥900 pg/mL. The median follow-up period was 31 days (interquartile range: 11–90 days). In cumulative incidence analysis, higher levels of hsTnI and NT-proBNP were associated with significantly higher mortality (hsTnI: <5 ng/L group; 8.8%, 5 ng/L to 99%ile URL group; 19%, and ≥99%ile URL group; 37%, P<0.001, and NT-proBNP: <125 pg/mL group; 7.8%, 125 to 900 pg/mL group; 21%, and ≥900 pg/mL group; 45%, P<0.001). The adjusted risk for all-cause death remained significant for each threshold of cardiac biomarkers (hsTnI ≥99%ile URL: hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.11–3.54, P=0.02, and NT-proBNP ≥900 pg/mL: HR 3.60, 95% CI 1.86–6.98, P<0.001).
Conclusion
Elevation of hsTnI or NT-proBNP was associated with poor prognosis in the current relatively severely ill COVID-19 patients. Measuring hsTnI or NT-proBNP can be an attractive option for risk stratification and deciding appropriate management in patients with COVID-19.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Institutional Research Fund at Kobe City Medical Center General Hospital
Collapse
Affiliation(s)
- M Sano
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - T Toyota
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - T Morimoto
- Kobe City Medical Center General Hospital, Center for Clinical Research and Innovation , Kobe , Japan
| | - T Okada
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - T Taniguchi
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - K Kim
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - N Ehara
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - M Kinoshita
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| | - A Doi
- Kobe City Medical Center General Hospital, Department of Infectious Diseases , Kobe , Japan
| | - K Tomii
- Kobe City Medical Center General Hospital, Department of Respiratory Medicine , Kobe , Japan
| | - Y Kihara
- Kobe City Medical Center General Hospital , Kobe , Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine , Kobe , Japan
| |
Collapse
|
6
|
Takai S, Ohashi M, Suzuki Y, Sasaki Y, Kakuda T, Broens EM, Wagenaar JA, van Duijkeren E. Virulence plasmids in clinical isolates of Rhodococcus equi from sick foals in the Netherlands. Lett Appl Microbiol 2022; 75:908-912. [PMID: 35707941 DOI: 10.1111/lam.13769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 06/01/2022] [Accepted: 06/10/2022] [Indexed: 11/30/2022]
Abstract
Clinical samples from 123 foals with suspected rhodococcosis submitted to the Veterinary Microbiological Diagnostic Centre of the Faculty of Veterinary Medicine between 1993 and 2006 were tested for the presence of the virulence gene vapA. Of the 123 samples, 120 were vapA-positive and 3 vapA-negative Rhodococcus equi were isolated. The 120 vapA-positive R. equi were isolated from 70 tracheal wash, 19 lung tissues, 7 lymph nodes, 6 synovial fluids, 13 abscesses or pus and single isolates from the uterus, gut, cerebrospinal fluid, abdomen fluid and faeces. Of the 120 isolates, 46 were from Dutch warmblood horses, 23 from Friesian horses, 14 from Trotters, 4 from Holsteiners, 3 from Arab breed, 2 from ponies, 1 from a Welsh pony and 27 from undefined breed horses. Using plasmid profile analysis of the 120 isolates, 117 isolates contained the 85-kb type I plasmid, 2 contained the 87-kb type I plasmid and 1 contained the novel 52-kb non-mobilizable virulence plasmid reported recently. These results showed that the virulent R. equi strains harbouring a virulence plasmid of 85-kb type I or 87-kb type I, which have been detected in clinical isolates from five European countries, are widespread in the Netherlands. This is the first report of plasmid types of clinical R. equi isolates in the Netherlands.
Collapse
Affiliation(s)
- S Takai
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | - M Ohashi
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | - Y Suzuki
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | - Y Sasaki
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | - T Kakuda
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | - E M Broens
- Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, the Netherlands
| | - J A Wagenaar
- Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, the Netherlands
| | - E van Duijkeren
- National Institute for Public Health and the Environment, Bilthoven, the Netherlands
| |
Collapse
|
7
|
Sasaki Y, Sakaguchi C, Satoh E. Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval? Ann Oncol 2022; 33:984-985. [PMID: 35636622 DOI: 10.1016/j.annonc.2022.05.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 05/13/2022] [Indexed: 11/28/2022] Open
Affiliation(s)
- Y Sasaki
- Department of Medical Oncology, Rakuwakai-Otowa Hospital, Kyoto, Japan; Department of Medical Oncology, Showa-University, Tokyo, Japan.
| | - C Sakaguchi
- Department of Medical Oncology, Rakuwakai-Otowa Hospital, Kyoto, Japan
| | - E Satoh
- Department of Medical Oncology, Rakuwakai-Otowa Hospital, Kyoto, Japan; Department of Medical Oncology, Showa-University, Tokyo, Japan
| |
Collapse
|
8
|
Inoue K, Shiozaki M, Sasaki S, Sasaki Y, Tamura H, Fukuda K, Kubota N, Hiki M, Funamizu T, Sumiyoshi M, Minamino T. Determination of physiological cardiac myosin-binging protein levels (cMyc) in healthy populations. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cardiac myosin–binding protein C (cMyC) is a cardiac-restricted protein that has more abundant, rapid release and clearance kinetics than cardiac troponin. The current ESC guideline suggests the cMyC may provide value as an alternative to cardiac troponin. The 99th percentile value is universally endorsed as the reference cut off to aid in the diagnosis of acute myocardial infarction (AMI), however, none of the report of healthy population of cMyC.
Purpose
The aim of this study was to evaluate the distribution of cMyC values in healthy subjects.
Methods
We used two cohorts in this retrospective study. 1) Healthy subjects; a total of 500 subjects (250 men and 250 women) who had annual health examinations in 2012 in the area of Kamigoto, a suburb of Nagasaki city in Southern Japan were enrolled. All participants showed none of abnormal findings including cell blood counts, chemical analysis, liver function tests, general urine tests, occult blood tests of stool, barium swallow, mammography for women, abdominal ultrasound sonography, and electrocardiogram. All blood samples were obtained in a fasting state in the morning. 2) Chest pain subjects; we collected samples from 250 subjects including 50 with non-ST elevation myocardial infarction visited admitted to a university hospital for measurement of high-sensitivity troponin T and coronary artery assessment by coronary angiography. We measured cMyC level in both cohorts by HISCL™-800 system (Sysmex corporation, Japan). The assay has a limit of detection of 0.5 ng/L and a lower limit of quantification of 1.3 ng/L.
Result
In healthy subjects, median age (IQR) was 44 (20, 82) in men and 50 (23, 91) in women. The 99th percentile of cMyC was 27.3 ng/L, which was around one-third lower than that in previous report (87 ng/L). In chest pain subjects, the concentrations of cMyC at presentation were significantly higher in those with versus without AMI (median, 66 ng/L versus 10 ng/L, P<0.001). Discriminatory power for AMI, as quantified by the area under the receiver-operating characteristic curve (AUC), was comparable for cMyC (AUC, 0.85 (95% CI 0.79–0.91) and hs-cTnT (AUC, 0.81 (95% CI 0.76–0.88)).
Conclusion
We defined the normal range of cMyC in healthy Japanese subjects. The level of cMyC at presentation provides discriminatory power comparable to hs-cTnT in the diagnosis of AMI. To determine the physiological value of a biomarker may be necessary to evaluate enough information about their health status.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Grant-in-Aid for Scientific Research
Collapse
Affiliation(s)
- K Inoue
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Shiozaki
- Tokyo Metropolitan Tama Medical Center, Cardiology, Tokyo, Japan
| | - S Sasaki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Sasaki
- Sysmex R&D Center Europe GmbH, Hamburg, Germany
| | - H Tamura
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Fukuda
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Kubota
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Hiki
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Funamizu
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Sumiyoshi
- Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Minamino
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
9
|
Kawakami H, Inoue K, Nagai T, Fujii A, Sasaki Y, Shikano Y, Sakuoka N, Miyazaki M, Takasuka Y, Ikeda S, Yamaguchi O. Left atrial dysfunction still exists in patients who obtain normal left atrial volume after successful ablation of atrial fibrillation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Atrial fibrillation (AF) promotes left atrial (LA) remodeling and vice versa. LA volume index (LAVI) ≥34 mL/m2 is an established cut-off value for identifying an enlarged left atrium. Catheter ablation has become an established therapy for AF and provides a reduction of LA volume by maintaining sinus rhythm (reverse remodeling). However, the definition of LA reverse remodeling after AF ablation is undetermined.
Purpose
We hypothesized that patients with LA dilatation who obtain normal LA volume (LAVI <34 mL/m2) after AF ablation would have better long-term outcomes than those who do not. Furthermore, we investigated whether patients with a normal LA volume could also obtain normal LA function with AF ablation.
Methods
We enrolled 140 AF patients with baseline LAVI ≥34 mL/m2, without AF recurrence for 1 year after the initial AF ablation. We acquired conventional and speckle-tracking echocardiographic parameters within 24 h and at 1 year after the procedure. Late recurrence was defined as AF recurrence >1 year after the initial ablation. To define the normal range of LA function, age-and sex-matched 140 controls without a history of AF were also enrolled.
Results
After restoration of sinus rhythm, overall LA structural and functional parameters were significantly improved, and 75 patients (54%) had normal LA volume at the time of follow-up (Table). During a median follow-up of 44 (31–61) months, 32 patients (23%) experienced a late recurrence of AF. Patients who obtained normal LA volume after AF ablation had fewer late recurrences than those who did not (P<0.01) (Figure). However, LA functional abnormalities still existed in AF patients, even if LA volume was normalized as in controls (Table).
Conclusion
Patients who obtain normal LA volume have better long-term outcomes of AF ablation than those who do not. Although AF ablation promotes beneficial effects on LA structure and function, LA function cannot be normalized even in patients who obtain normal LA volume after successful ablation. Thus, physicians should carefully consider long-term follow-up and residual AF risks, regardless of sinus rhythm restoration by catheter ablation.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - K Inoue
- Ehime University, Toon, Japan
| | - T Nagai
- Ehime University, Toon, Japan
| | - A Fujii
- Ehime University, Toon, Japan
| | | | | | | | | | | | - S Ikeda
- Ehime University, Toon, Japan
| | | |
Collapse
|
10
|
Takai S, Sudo M, Sakai M, Suzuki K, Sasaki Y, Kakuda T, Suzuki Y. Isolation of Rhodococcus equi from the gastrointestinal contents of earthworms (family Megascolecidae). Lett Appl Microbiol 2021; 74:27-31. [PMID: 34608644 DOI: 10.1111/lam.13577] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Revised: 09/29/2021] [Accepted: 10/01/2021] [Indexed: 11/27/2022]
Abstract
Rhodococcus equi was isolated from the gastrointestinal contents of earthworms (family Megascolecidae) and their surrounding soil collected from pastures of two horse-breeding farms in Aomori Prefecture, outdoor pig pens, forest in Towada campus, orange groves and forest where wild boars (Sus scrofa) are established in Tanabe, Wakayama Prefecture. The number of R. equi in the lower gastrointestinal contents of 23 earthworms collected from our campus was significantly larger than that of the upper gastrointestinal content. The mean numbers of R. equi from the gastrointestinal contents of earthworms collected from the various places were 2·3-fold to 39·7-fold more than those of the surrounding soil samples. In all, 1771 isolates from the earthworms and 489 isolates from the soil samples were tested for the presence of vapA and vapB genes using polymerase chain reaction. At the horse-breeding farm N, 9 of the 109 isolates (8·3%) from the earthworms and 7 of the 106 isolates (6·6%) from the soil samples were positive for the vapA gene. At the University's forest, one of the 250 isolates (0·4%) from the gastrointestinal contents of the earthworm was positive for the vapB gene. These results revealed that R. equi can be found in significant quantities in the gastrointestinal contents of earthworms, suggesting that they act as an accumulator of R. equi in the soil environment and as a source or reservoir of animal infection.
Collapse
Affiliation(s)
- S Takai
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| | - M Sudo
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| | - M Sakai
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| | - K Suzuki
- Hikiiwa Park Center, Tanabe, Japan
| | - Y Sasaki
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| | - T Kakuda
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| | - Y Suzuki
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan
| |
Collapse
|
11
|
Kaneko S, Ito K, Yuki S, Harada K, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Tsuji Y, Ando T, Kato K, Wakabayashi T, Kotaka M, Takahashi Y, Sakata Y, Komatsu Y. P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Yoshikawa A, Ito K, Yuki S, Kawamoto Y, Saito R, Yamamura T, Yagisawa M, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Sakata Y, Komatsu Y. P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Ito K, Yuki S, Nakano S, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Tateyama M, Sogabe S, Matsumoto R, Sakata Y, Komatsu Y. P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Katayama K, Nakashima S, Ishida H, Kubota Y, Nakano M, Fukami T, Sasaki Y, Fujita KI, Nakajima M. Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients. Noncoding RNA Res 2021; 6:123-129. [PMID: 34322648 PMCID: PMC8283029 DOI: 10.1016/j.ncrna.2021.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 06/24/2021] [Accepted: 06/24/2021] [Indexed: 11/21/2022] Open
Abstract
Single nucleotide polymorphisms in genes encoding microRNAs (miRNA-SNPs) may affect the maturation steps of miRNAs or target mRNA recognition, leading to changes in the expression of target mRNAs to cause gain- or loss-of-function changes. Several miRNA-SNPs are known to be associated with the risk of diseases such as cancer. The purpose of this study was to comprehensively determine the miRNA-SNPs in Japanese individuals to evaluate the differences in allele frequencies between ethnicities by comparing data from the global population in the 1000 Genomes Project and differences between healthy subjects and cancer patients. We performed next-generation sequencing targeting genes encoding 1809 pre-miRNAs. As a result, 403 miRNA-SNPs (146 miRNA-SNPs per subject on average) were identified in 28 healthy Japanese subjects. We observed significant differences in the allele frequencies between ethnicities in 33 of the 403 miRNA-SNPs. The numbers of miRNA-SNPs per subject in 44 non-small cell lung cancer (NSCLC), 33 colorectal cancer (CRC), and 15 soft tissue sarcoma (STS) patients were almost equal to those in healthy subjects. Significant differences in allele frequencies were observed for 14, 11, and 9 miRNA-SNPs in NSCLC, CRC, and STS patients compared with the frequencies in healthy subjects, suggesting that these SNPs can be biomarkers of risk for each type of cancer assessed. In summary, we comprehensively characterized miRNA-SNPs in Japanese individuals and found differences in allele frequencies of several miRNA-SNPs between ethnicities and between healthy subjects and cancer patients. Studies investigating a larger number of subjects should be performed to confirm the potential of miRNA-SNPs as biomarkers of cancer risk.
Collapse
Key Words
- 3′-UTR, 3′-untranslated region
- BWA, Burrows-Wheeler Aligner
- Biomarker
- CI, confidence interval
- CRC, colorectal cancer
- GATK, Genome Analysis Toolkit
- InDel, insertion or deletion mutation
- NGS
- NGS, next-generation sequencing
- NSCLC, non-small cell lung cancer
- Polymorphisms
- SNP, single nucleotide polymorphism
- STS, soft tissue sarcoma
- mOR, modified odds ratio
- miRNA, microRNA
- microRNA
- pre-miRNA, precursor miRNA
Collapse
Affiliation(s)
- Koki Katayama
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Shimon Nakashima
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Hiroo Ishida
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Yutaro Kubota
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Masataka Nakano
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.,WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Tatsuki Fukami
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.,WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Ken-Ichi Fujita
- Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Miki Nakajima
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.,WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan
| |
Collapse
|
15
|
Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemother Pharmacol 2021; 88:543-553. [PMID: 34117512 DOI: 10.1007/s00280-021-04314-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 06/05/2021] [Indexed: 01/08/2023]
Abstract
PURPOSE SN-38, a pharmacologically active metabolite of irinotecan, is taken up into hepatocytes by organic anion transporting polypeptide (OATP) 1B1. The effects of functional OATP1B1 521T>C on the pharmacokinetics of SN-38 remain controversial. Here, we prospectively examined the effects of OATP1B1 function on the area under the plasma total or unbound concentration-time curve (tAUC or uAUC) of SN-38 by assessing OATP1B1 521T>C and the plasma levels of endogenous OATP1B1 substrates, coproporphyrin (CP)-I and III, in cancer patients treated with irinotecan. METHODS We enrolled cancer patients who were treated with an irinotecan-containing regimen and did not have severe renal failure. The total and unbound concentrations of SN-38 in the plasma were measured by high-performance liquid chromatography. AUC values were calculated and normalized to the actual irinotecan dose (AUC/dose). The OATP1B1 521T>C was analyzed by direct sequencing. Concentrations of the endogenous substrates in plasma before irinotecan treatment (baseline) were determined by liquid chromatography with tandem mass spectrometry. RESULTS Twenty-two patients with a median estimated glomerular filtration rate of 74.8 mL/min (range 32.6-99.6) were examined. Both tAUC/dose and uAUC/dose were associated with the grade of neutropenia; however, they were not associated with OATP1B1 521T>C or baseline CP-I and III levels. It is worth noting that these baseline concentrations were significantly higher in patients with OATP1B1 521C, supporting functional changes in OATP1B1. CONCLUSION The contribution of OATP1B1 activity to inter-patient variability in the systemic exposure to SN-38 is likely minimal in patients without severe renal failure.
Collapse
Affiliation(s)
- Ayako Tsuboya
- Division of Pharmaceutical Regulatory Pharmacy, Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.,Department of Pharmacy, Kawasaki Municipal Tama Hospital, 1‑30‑37, Shukugawara, Tama‑ku, Kawasaki, Kanagawa, 214‑8525, Japan
| | - Yutaro Kubota
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Hiroo Ishida
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Ryotaro Ohkuma
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Tomoyuki Ishiguro
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Yuya Hirasawa
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Hirotsugu Ariizumi
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Takuya Tsunoda
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Natsumi Matsumoto
- Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Yusuke Kondo
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongou, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Yukana Tomoda
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongou, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Hiroyuki Kusuhara
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongou, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Ken-Ichi Fujita
- Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
| |
Collapse
|
16
|
Takahashi K, Miyaji Y, Ohkuma R, Higuchi H, Komohara Y, Aida S, Yashima J, Yamamoto H, Suzawa K, Takahashi Y, Toyooka S, Ashimine H, Oyama Y, Narahara H, Yotsumoto J, Ishida H, Tsunoda T, Sasaki Y, Ono Y, Teraoka S. Accumulation of genome-wide somatic loss of heterozygosity (LOH) as a prominent feature of advanced malignant soft tissue tumors and association with the BRCAness status, suppression of immune responses, and lower survival rates. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.11533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11533 Background: Malignant soft tissue tumor is a rare cancer with few therapeutic options. Recent genomic analysis revealed widespread CNA and the cumulative burden of cancer-related pathogenic germline mutations/variants, their clinical and therapeutic significance were unknown. Methods: We recruited 155 patients with advanced malignant soft tissue tumors (135 female and 20 male, mean age 51 at analysis, 100 LMS, 19 LPS, 4 ESS, 3 UPS, 3 AS, 3 MPT, 3 GIST and others) with confirmed metastasis/recurrence and information on familial cancer burden. Whole exome sequencing was performed in both blood and tumor samples as described in 2018ASCO. The copy number of BRCA2 gene was determined by the MLPA method. Tumor immune microenvironment was assessed by immunohistochemistry. The MSI status was analysed by PCR. Results: We analyzed the LOH status in 595 COSMIC genes and found that genome-wide accumulation of somatic LOH of polygenic germline mutations/variants. Patients with more than 33% LOH genes (n=102) in the total of somatic and LOH mutations showed significantly lower OS rates compared with those (n=53) with less LOH genes (5-year survival rates; 49 vs 75%, p=0.010), which constitute 78% of LMS (n=78/100) and 26% of LPS (n=5/19). Total of 41 patients (26%, n=41/155) including 33 LMS (33%, n=33/100) showed LOH in the BRCA2 locus with hemizygous VUS. Those patients with BRCA2 LOH (n=41) showed significantly lower OS rates compared with those without BRCA2 LOH (n=114) (5-year survival rates; 43 vs. 64%, p=0.019). Neither TMB nor the MSI status was associated with LOH. In contrast, accumulation of somatic LOH (mean LOH values of 71.7 vs. 15.7%) was clearly and negatively associated with CD8+T-cell immune infiltrates (T-cells; 44±23 vs 555±180/mm2, n=7, p=0.016), CD20+B-cell accumulation in tertiary lymphoid structures (TLS) (TLS; 0.57±0.43 vs. 20.1±6.1/tumor, n=7, p=0.008) and low levels of neutrophil-to-lymphocyte ratio (NLR) (NLR; 3.63±0.45 vs. 1.71±0.17, n=7, p=0.002), hallmarks of the immunological response to tumors. Conclusions: This study suggests that in advanced malignant soft tissue tumors, accumulation of genome-wide LOH of germline mutations/variants is associated with the BRCAness status and suppression of the immune responses to tumors, and thus influences therapeutic response and survival of the patients.
Collapse
Affiliation(s)
- Katsuhito Takahashi
- Kameda Medical Center, Center for Multidisciplinary Treatment of Sarcoma, Department of Sarcoma Medicine, Kamogawa, Japan
| | - Yasutomo Miyaji
- Kameda Medical Center, Department of Medical Oncology, Kamogawa, Japan
| | - Ryotaro Ohkuma
- Showa University School of Medicine, Department of Medical Oncology, Tokyo, Japan
| | - Hajime Higuchi
- International University of Health and Welfare, Narita Hospital, Department of Clinical Oncology, Narita, Japan
| | - Yoshihiro Komohara
- Kumamoto University, Graduate School of Medical Sciences, Department of Cell Pathology, Kumamoto, Japan
| | - Shinsuke Aida
- International University of Health and Welfare, Mita Hospital, Department of Pathology, Tokyo, Japan
| | - Jun Yashima
- Kameda Medical Center, Departments of Surgical Oncology and Sarcoma Medicine, Kamogawa, Japan
| | - Hiromasa Yamamoto
- Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama, Japan
| | - Ken Suzawa
- Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama, Japan
| | - Yuko Takahashi
- Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama, Japan
| | - Shinichi Toyooka
- Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama, Japan
| | - Hiroya Ashimine
- Kameda Medical Center, Departments of Medical Oncology, Kamogawa, Japan
| | - Yu Oyama
- Kameda Medical Center, Department of Medical Oncology, Kamogawa, Japan
| | - Hiroyuki Narahara
- Hyogo Prefectural Nishinomiya Hospital, Department of Medical Oncology, Nishinomiya, Japan
| | - Junko Yotsumoto
- Graduate School of International University of Health and Welfare, Department of Genetic Counseling, Tokyo, Japan
| | - Hiroo Ishida
- Showa University Northern Yokohama City Hospital, Department of Medical Oncology, Yokohama, Japan
| | - Takuya Tsunoda
- Showa University School of Medicine, Department of Medical Oncology, Tokyo, Japan
| | | | - Yasuo Ono
- Kameda Medical Center, Department of Surgical Oncology, Kamogawa, Japan
| | - Satoshi Teraoka
- Kameda Medical Center, Department of Surgical Oncology, Kamogawa, Japan
| |
Collapse
|
17
|
Takamura T, Motosugi U, Ogiwara M, Sasaki Y, Glaser KJ, Ehman RL, Kinouchi H, Onishi H. Relationship between Shear Stiffness Measured by MR Elastography and Perfusion Metrics Measured by Perfusion CT of Meningiomas. AJNR Am J Neuroradiol 2021; 42:1216-1222. [PMID: 33985944 DOI: 10.3174/ajnr.a7117] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 01/10/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE When managing meningiomas, intraoperative tumor consistency and histologic subtype are indispensable factors influencing operative strategy. The purposes of this study were the following: 1) to investigate the correlation between stiffness assessed with MR elastography and perfusion metrics from perfusion CT, 2) to evaluate whether MR elastography and perfusion CT could predict intraoperative tumor consistency, and 3) to explore the predictive value of stiffness and perfusion metrics in distinguishing among histologic subtypes of meningioma. MATERIALS AND METHODS Mean tumor stiffness and relative perfusion metrics (blood flow, blood volume, and MTT) were calculated (relative to normal brain tissue) for 14 patients with meningiomas who underwent MR elastography and perfusion CT before surgery (cohort 1). Intraoperative tumor consistency was graded by a neurosurgeon in 18 patients (cohort 2, comprising the 14 patients from cohort 1 plus 4 additional patients). The correlation between tumor stiffness and perfusion metrics was evaluated in cohort 1, as was the ability of perfusion metrics to predict intraoperative tumor consistency and discriminate histologic subtypes. Cohort 2 was analyzed for the ability of stiffness to determine intraoperative tumor consistency and histologic subtypes. RESULTS The relative MTT was inversely correlated with stiffness (P = .006). Tumor stiffness was positively correlated with intraoperative tumor consistency (P = .01), while perfusion metrics were not. Relative MTT significantly discriminated transitional meningioma from meningothelial meningioma (P = .04), while stiffness did not significantly differentiate any histologic subtypes. CONCLUSIONS In meningioma, tumor stiffness may be useful to predict intraoperative tumor consistency, while relative MTT may potentially correlate with tumor stiffness and differentiate transitional meningioma from meningothelial meningioma.
Collapse
Affiliation(s)
- T Takamura
- From the Department of Radiology (T.T.), Shizuoka General Hospital, Shizuoka, Japan .,Department of Radiology (T.T.), Juntendo University, Tokyo, Japan
| | - U Motosugi
- Department of Radiology (U.M.), Kofu-Kyoritsu Hospital, Yamanashi, Japan
| | - M Ogiwara
- Departments of Neurosurgery (M.O., H.K.)
| | - Y Sasaki
- Radiology (Y.S., H.O.), University of Yamanashi, Yamanashi, Japan
| | - K J Glaser
- Department of Radiology (K.J.G., R.L.E.), Mayo Clinic College of Medicine, Rochester, Minnesota
| | - R L Ehman
- Department of Radiology (K.J.G., R.L.E.), Mayo Clinic College of Medicine, Rochester, Minnesota
| | - H Kinouchi
- Departments of Neurosurgery (M.O., H.K.)
| | - H Onishi
- Radiology (Y.S., H.O.), University of Yamanashi, Yamanashi, Japan
| |
Collapse
|
18
|
Satoh E, Saito T, Kajimoto K, Asai T, Amano A, Yoshida A, Sasaki Y. P22.01 A Case of Intimal Sarcoma with Osteosarcomatous Differentiation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Sato A, Omura M, Minagawa Y, Takino K, Matsui K, Hongo H, Shirata R, Hashimoto H, Misumi T, Sasaki Y, Inoue T, Hata M. PO-1258: Intensity modulated radiation therapy for lymph node oligo-recurrence. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01276-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Kinoshita M, Inoue K, Akazawa Y, Nakagawa H, Sasaki Y, Higashi H, Fujii A, Uetani T, Aono J, Nagai T, Nishimura K, Ikeda S, Yamaguchi O. Impact of right ventricular contractile reserve on exercise capacity in patients with heart failure: clinical application of low-load exercise stress echocardiography. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The peak oxygen uptake (VO2) evaluated by the cardiopulmonary exercise test (CPX) is an established marker of exercise capacity in patients with heart failure (HF). In particular, peak VO2 <14 ml/kg/min is used to be one of the criteria for heart transplantation. However, given exercise intolerance in patients with HF, it is difficult for refractory HF patients to reach sufficient exercise load. A recent report has highlighted significant impact of right ventricular (RV) function on mortality and urgent heart transplantation. Taken together, we hypothesized that the assessment of RV function was helpful to predict exercise capacity by using low-load exercise stress echocardiography (low-load ESE) in patients with HF.
Purpose
We evaluated whether RV dysfunction assessed by the low-load ESE determined a low peak VO2 <14 ml/kg/min in patients with HF.
Methods
We studied 67 consecutive hospitalized patients with HF (mean age, 65 years; 75% male; mean LV ejection fraction, 36%) who underwent ESE and CPX after stabilized HF condition, and the time interval of CPX and ESE tests was within 48 hours. CPX was performed using an upright cycle ergometer by a ramp protocol, while ESE was performed using ergometer in semi-supine position and the workload was generally increased by 25 watts every 3 minutes. The low-load ESE was defined as the 25 watts exercise. The increments of RV s' velocity at tricuspid annulus and RV strain in the free wall were considered as a preservation of RV contractile reserve. Among the study population, 26 patients were performed right heart catheterization and RV dP/dt/Pmax was estimated as an invasive marker of RV contractility.
Results
The achieved intensity of exercise was 50.4±21.0 watts, and all patients completed the low-load ESE. The invasive study showed that the change of RV s' velocity during the low-load ESE significantly correlated with RV dP/dt/Pmax (r=0.706, p<0.001). As shown in Figure, the non-invasive parameters of RV contractile reserve during the low-load ESE were significantly correlated with peak VO2 (RV s' velocity: r=0.787, p<0.001; RV strain: r=0.244, p=0.047). ROC analysis showed that the change of RV s' velocity during the low-load ESE correctly identified patients with peak VO2 <14 ml/kg/min (AUC=0.95, sensitivity 92.3%, specificity 85.2%). In terms of inter- and intra-observer variabilities, ICCs of the change of RV s' velocity were 0.86 and 0.96, and ICCs of the changes of RV strain were 0.63 and 0.70, respectively.
Conclusion
The change of RV s' velocity during the low-load ESE could determine exercise tolerance in patients with HF. The assessment of RV contractile reserve might be clinically useful to discriminate high risk HF patients.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - K Inoue
- Ehime University, Toon, Japan
| | | | | | | | | | - A Fujii
- Ehime University, Toon, Japan
| | | | - J Aono
- Ehime University, Toon, Japan
| | - T Nagai
- Ehime University, Toon, Japan
| | | | - S Ikeda
- Ehime University, Toon, Japan
| | | |
Collapse
|
21
|
Toyota T, Morimoto T, Kitai T, Park M, Sasaki Y, Kim K, Ehara N, Kobori A, Kinoshita M, Kaji S, Furukawa Y, Kimura T. Biodegradable-polymer versus durable-polymer drug eluting stents for coronary artery disease: systematic review and a meta-analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Biodegradable polymer drug-eluting stents (BP-DES) has been developed to overcome the potential drawbacks of the first-generation durable polymer drug-eluting stents (DP-DES). However, it is still under debate whether BP-DES is associated with superior efficacy and safety over DP-DES.
Purpose
We sought to compare the effects of BP-DES and DP-DES in patients with coronary artery disease.
Methods
We performed systematic review and a meta-analysis of randomized controlled trials comparing BP-DES and DP-DES on clinical outcomes in patients with coronary artery disease using CE-mark approved drug-eluting stents (DES) with at least 1-year follow-up. We included 32 studies involving 39,686 patients (BP-DES: 21,439 patients, and DP-DES: 18,247 patients). Primary outcome measure was target vessel failure (TVF; equivalent to the composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target vessel revascularization). We performed subgroup analysis according to the DP-DES generations (newer-generation DP-DES: 15,179patients, and first-generation DP-DES: 3,068 patients), and the effects of newer-generation DP-DES was compared with the BP-DES according to the BP-DES strut thickness (Ultra-thin strut [<80μm]: 7,572 patients, Thin-strut [80–100μm]: 5,465 patients, and Thick-strut [≥80μm]: 5,876 patients).
Results
The odds for TVF was not significantly different between the BP-DES group and the DP-DES group in the entire study population (odds ratio [OR] 0.96, 95% confidence interval [CI] [0.90–1.02], P=0.20). The odds for TVF was significantly low in the BP-DES group relative to the first-generation DP-DES group, however the odds were comparable between the BP-DES group and the newer-generation DP-DES group (BP-DES versus first-generation DP-DES: OR 0.82, 95% CI [0.73–0.92], P<0.001, and BP-DES versus newer-generation DP-DES: OR 1.00, 95% CI [0.93–1.08], P=0.99). We also found no significant differences between the BP-DES and newer-generation DP-DES, in all subgroups stratified by the BP-DES strut thickness (Ultra-thin strut BP-DES versus newer-generation DP-DES: OR 0.88, 95% CI [0.76–1.02], P=0.10, Thin-strut BP-DES versus newer-generation DP-DES: OR 1.01, 95% CI [0.90–1.13], P=0.89, and Thick strut BP-DES versus newer-generation DP-DES: OR 1.11, 95% CI [0.99–1.25], P=0.08).
Conclusions
In this meta-analysis of randomized controlled trials evaluating clinical outcomes, there was no significant differences between BP-DES and DP-DES. We found beneficial effects of BP-DES relative to the first-generation DP-DES, however, there was no statistical differences between BP-DES and newer-generation DP-DES, irrespective of the BP-DES strut thickness.
Pooled odds ratios for clinical outcomes
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Toyota
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - T Morimoto
- Hyogo College of Medicine, Department of Clinical Epidemiology, Nishinomiya, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - M Park
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - K Kim
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - N Ehara
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - M Kinoshita
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - S Kaji
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine, Kobe, Japan
| | - T Kimura
- Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
| |
Collapse
|
22
|
Pak M, Kobori A, Shizuta S, Sasaki Y, Toyota T, Yoshizawa T, Inoue K, Kaitani K, Kurotobi T, Morishima I, Kusano K, Kimura T, Furukawa Y. The impact of catheter ablation for patients with asymptomatic atrial fibrillation: subanalysis of kansai plus atrial fibrillation (kpaf) registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Catheter ablation (CA) of atrial fibrillation (AF) for symptomatic patients improves the quality of life and prognosis of patients with heart failure. However, the impact of CA for asymptomatic patients is still controversial.
Purpose
We aimed to investigate the clinical outcomes of CA of AF for asymptomatic patients compared to those for symptomatic patients.
Methods
A total of 5,013 patients from the Kansai Plus Atrial Fibrillation (KPAF) Registry who underwent CA were screened. The patients were divided into three groups by type of AF; paroxysmal (PAF), persistent (PEAF) and long standing (LSAF) and the patients in each type of AF were divided into two groups: asymptomatic and symptomatic. The primary endpoint was recurrent supraventricular tachyarrhythmias lasting for more than 30 seconds during follow-up 4 years after CA. The secondary endpoint was a composite of cardiovascular, cerebral, and gastrointestinal events during follow-up 4 years after CA. The incidence of complications related to CA between asymptomatic and symptomatic patients was also evaluated. Kaplan–Meier analysis was employed to estimate the primary and secondary endpoints. The statistical differences in primary and secondary endpoints between asymptomatic and symptomatic patients were evaluated using a log–rank test. The impact of symptom due to AF on the primary and secondary endpoint was evaluated using a Cox hazard analysis. The difference in incidence of complications between asymptomatic and symptomatic patients was evaluated using a chi–square test.
Results
In this study population, PAF was the most frequent at 64.4%, followed by PEAF (22.7%) and LSAF (13.0%). There were some significant differences in the baseline characteristics between asymptomatic and symptomatic patients in each type of AF. The proportion of male was significantly higher in asymptomatic patients than symptomatic patients in PAF (81.2% versus 67.2%, p<0.001) and PEAF (86.4% versus 74.3%, p<0.001). Left atrial diameter was larger in asymptomatic patients than symptomatic patients only in PAF (40±6mm versus 38±6mm, p<0.001). In all types of AF, there was no significant difference in primary endpoint between asymptomatic and symptomatic patients as follows: 37.5% versus 40.6% (p=0.6) in PAF, 45.2% versus 55.1% (p=0.09) in PEAF and 59.3% versus 63.6% (p=1.0) in LSAF. There was also no significant difference in secondary endpoint between asymptomatic and symptomatic patients: 7.1% versus 6.8% (p=0.7) in PAF, 5.4% versus 8.7% (p=0.3) in PEAF and 4.4% versus 5.1% (p=0.5) in LSAF. In a Cox hazard analysis, the symptom did not affect both of the primary and secondary endpoints in each type of AF. In regard to the incidence of complications related to CA, there was no significant difference between asymptomatic and symptomatic patients in each type of AF.
Conclusion
CA of AF for asymptomatic patients can be safe and can lead to equivalent outcomes as well as symptomatic patients.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Pak
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - S Shizuta
- Kyoto University Graduate School of Medicine, Cardiovascular Medicine, Kyoto, Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - T Toyota
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - T Yoshizawa
- Kyoto University Graduate School of Medicine, Cardiovascular Medicine, Kyoto, Japan
| | - K Inoue
- Sakurabashi-Watanabe Hospital, Cardiovascular center, Osaka, Japan
| | - K Kaitani
- Japanese Red Cross Otsu Hospital, Otsu, Japan
| | - T Kurotobi
- Namba Kurotobi Heart Clinic, Osaka, Japan
| | | | - K Kusano
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - T Kimura
- Kyoto University Graduate School of Medicine, Cardiovascular Medicine, Kyoto, Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Kobe, Japan
| |
Collapse
|
23
|
Takai S, Sawada N, Nakayama Y, Ishizuka S, Nakagawa R, Kawashima G, Sangkanjanavanich N, Sasaki Y, Kakuda T, Suzuki Y. Reinvestigation of the virulence of Rhodococcus equi isolates from patients with and without AIDS. Lett Appl Microbiol 2020; 71:679-683. [PMID: 32920889 DOI: 10.1111/lam.13386] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 09/02/2020] [Accepted: 09/03/2020] [Indexed: 11/29/2022]
Abstract
Rhodococcus equi emerged as a zoonotic pathogen of human immunodeficiency virus-infected patients over the last three decades. Two virulence plasmid types of R. equi, pVAPA and pVAPB associated with equine and porcine isolates, have been recognized, and more recently, pVAPN, a novel host-associated virulence plasmid in R. equi, was found in bovine and caprine isolates. We reinvestigated 39 previously reported isolates of R. equi from patients with and without acquired immunodeficiency syndrome (AIDS) by detecting vapA, vapB and vapN using PCR and plasmid profiling. After excluding one isolate that could not be cultured from frozen storage, eight isolates carried a virulence plasmid encoding vapA (pVAPA), 10 carried a virulence plasmid encoding vapB (pVAPB), seven carried a virulence plasmid encoding vapN (pVAPN) and 13 were negative for those genes. Of the 29 isolates from patients with AIDS, 7, 10 and 5 harboured pVAPA, pVAPB and pVAPN respectively. Among nine isolates from patients without AIDS, one and two harboured pVAPA and pVAPN respectively. This study demonstrated that pVAPN-positive R. equi existed in human isolates before 1994 and reaffirmed that equine-associated pVAPA-positive, porcine-associated pVAPB-positive and bovine- or caprine-associated pVAPN-positive R. equi are widely spread globally. Because domestic animals might be major sources of human infection, further research is needed to reveal the prevalence of pVAPN-positive R. equi infection in cattle and goats.
Collapse
Affiliation(s)
- S Takai
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - N Sawada
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - Y Nakayama
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - S Ishizuka
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - R Nakagawa
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - G Kawashima
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - N Sangkanjanavanich
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan.,Faculty of Veterinary Medicine, Mahanakorn University of Technology, Bangkok, Thailand
| | - Y Sasaki
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - T Kakuda
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| | - Y Suzuki
- Laboratory of Animal Hygiene, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan
| |
Collapse
|
24
|
Shindo Y, Nakatsumi H, Yuki S, Kawamoto Y, Muto O, Dazai M, Harada K, Kobayashi Y, Sogabe S, Katagiri M, Kotaka M, Nakamura M, Hatanaka K, Ishiguro A, Tsuji Y, Kobayashi T, Tateyama M, Sasaki Y, Sasaki T, Takagi R, Sakata Y, Komatsu Y. P-112 HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
25
|
Fushitani M, Sasaki Y, Matsuda A, Fujise H, Kawabe Y, Hashigaya K, Owada S, Togashi T, Nakajima K, Yabashi M, Hikosaka Y, Hishikawa A. Multielectron-Ion Coincidence Spectroscopy of Xe in Extreme Ultraviolet Laser Fields: Nonlinear Multiple Ionization via Double Core-Hole States. Phys Rev Lett 2020; 124:193201. [PMID: 32469563 DOI: 10.1103/physrevlett.124.193201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 04/14/2020] [Indexed: 06/11/2023]
Abstract
Ultrafast multiphoton ionization of Xe in strong extreme ultraviolet free-electron laser (FEL) fields (91 eV, 30 fs, 1.6×10^{12} W/cm^{2}) has been investigated by multielectron-ion coincidence spectroscopy. The electron spectra recorded in coincidence with Xe^{4+} show characteristic features associated with two-photon absorption to the 4d^{-2} double core-hole (DCH) states and subsequent Auger decay. It is found that the pathway via the DCH states, which has eluded clear identification in previous studies, makes a large contribution to the multiple ionization, despite the long FEL pulse duration compared with the lifetime of the 4d core-hole states.
Collapse
Affiliation(s)
- M Fushitani
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
| | - Y Sasaki
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - A Matsuda
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
| | - H Fujise
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
| | - Y Kawabe
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - K Hashigaya
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - S Owada
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5198, Japan
| | - T Togashi
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5198, Japan
| | - K Nakajima
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5198, Japan
| | - M Yabashi
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5198, Japan
| | - Y Hikosaka
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Institute of Liberal Arts and Sciences, University of Toyama, Toyama 930-0194, Japan
| | - A Hishikawa
- Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
- RIKEN, SPring-8 Center, Sayo, Hyogo 679-5148, Japan
- Research Center for Materials Science, Nagoya University, Nagoya, Aichi 464-8602, Japan
| |
Collapse
|
26
|
Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients. Clin Pharmacol Ther 2020; 108:586-595. [PMID: 32034953 DOI: 10.1002/cpt.1810] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Accepted: 01/31/2020] [Indexed: 12/16/2022]
Abstract
Regorafenib treatment improves survival of patients with metastatic colorectal cancer, but it is also characterized by detrimental side effects that may require modified dosing or interval schedules. Regorafenib is metabolized by cytochrome P450 3A4 in the liver to its active metabolites, M-2 and M-5. We examined area under the unbound plasma concentration-time curve (AUCu) to these compounds to establish pharmacokinetic bases for individualized dosing strategies. The plasma protein binding of M-2 and M-5 was approximately 10-fold lower than that of regorafenib, whereas AUCu values for active metabolites on both days 1 and 15 were significantly higher than that of regorafenib. Patients with higher AUCu values of M-2 or M-5 on day 1 showed significantly shorter progression-free survival than others, likely due, at least in part, to treatment discontinuation as a result of adverse events, especially occurred during first cycle.
Collapse
Affiliation(s)
- Yutaro Kubota
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ken-Ichi Fujita
- Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan
| | - Takehiro Takahashi
- Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan
| | - Yu Sunakawa
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan
| | - Hiroo Ishida
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Kazuyuki Hamada
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Wataru Ichikawa
- Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan
| | - Takuya Tsunoda
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Kazuhiro Shimada
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Yusuke Masuo
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Yukio Kato
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
27
|
Mori D, Ishida H, Mizuno T, Kusumoto S, Kondo Y, Izumi S, Nakata G, Nozaki Y, Maeda K, Sasaki Y, Fujita KI, Kusuhara H. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. Drug Metab Dispos 2020; 48:387-394. [PMID: 32114508 DOI: 10.1124/dmd.119.089474] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Accepted: 01/28/2020] [Indexed: 12/18/2022] Open
Abstract
Paclitaxel has been considered to cause OATP1B-mediated drug-drug interactions at therapeutic doses; however, its clinical relevance has not been demonstrated. This study aimed to elucidate in vivo inhibition potency of paclitaxel against OATP1B1 and OATP1B3 using endogenous OATP1B biomarkers. Paclitaxel is an inhibitor of OATP1B1 and OATP1B3, with Ki of 0.579 ± 0.107 and 5.29 ± 3.87 μM, respectively. Preincubation potentiated its inhibitory effect on both OATP1B1 and OATP1B3, with Ki of 0.154 ± 0.031 and 0.624 ± 0.183 μM, respectively. Ten patients with non-small cell lung cancer who received 200 mg/m2 of paclitaxel by a 3-hour infusion were recruited. Plasma concentrations of 10 endogenous OATP1B biomarkers-namely, coproporphyrin I, coproporphyrin III, glycochenodeoxycholate-3-sulfate, glycochenodeoxycholate-3-glucuronide, glycodeoxycholate-3-sulfate, glycodeoxycholate-3-glucuronide, lithocholate-3-sulfate, glycolithocholate-3-sulfate, taurolithocholate-3-sulfate, and chenodeoxycholate-24-glucuronide-were determined in the patients with non-small cell lung cancer on the day before paclitaxel administration and after the end of paclitaxel infusion for 7 hours. Paclitaxel increased the area under the plasma concentration-time curve (AUC) of the endogenous biomarkers 2- to 4-fold, although a few patients did not show any increment in the AUC ratios of lithocholate-3-sulfate, glycolithocholate-3-sulfate, and taurolithocholate-3-sulfate. Therapeutic doses of paclitaxel for the treatment of non-small cell lung cancer (200 mg/m2) will cause significant OATP1B1 inhibition during and at the end of the infusion. This is the first demonstration that endogenous OATP1B biomarkers could serve as surrogate biomarkers in patients. SIGNIFICANCE STATEMENT: Endogenous biomarkers can address practical and ethical issues in elucidating transporter-mediated drug-drug interaction (DDI) risks of anticancer drugs clinically. We could elucidate a significant increment of the plasma concentrations of endogenous OATP1B biomarkers after a 3-hour infusion (200 mg/m2) of paclitaxel, a time-dependent inhibitor of OATP1B, in patients with non-small cell lung cancer. The endogenous OATP1B biomarkers are useful to assess the possibility of OATP1B-mediated DDIs in patients and help in appropriately designing a dosing schedule to avoid the DDIs.
Collapse
Affiliation(s)
- Daiki Mori
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Hiroo Ishida
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Tadahaya Mizuno
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Sojiro Kusumoto
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Yusuke Kondo
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Saki Izumi
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Genki Nakata
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Yoshitane Nozaki
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Kazuya Maeda
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Yasutsuna Sasaki
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Ken-Ichi Fujita
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| | - Hiroyuki Kusuhara
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (D.M., T.M., Y.K., G.N., K.M., H.K.); Division of Medical Oncology, Department of Medicine (H.I., Y.S.), and Division of Respiratory Medicine and Allergology, Department of Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan (S.I., Y.N.); and Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan (K.-i.F.)
| |
Collapse
|
28
|
Ogura I, Sasaki Y, Sue M, Oda T, Kameta A, Hayama K. Tc-99m hydroxymethylene diphosphonate SPECT/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value. Clin Radiol 2020; 75:46-50. [DOI: 10.1016/j.crad.2019.05.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Accepted: 05/24/2019] [Indexed: 12/13/2022]
|
29
|
Shiokawa R, Lee XP, Yamada M, Fujishiro M, Sakamaki H, Hasegawa C, Ishida H, Ikeda K, Fujita KI, Iwabuchi S, Onda H, Kumazawa T, Sasaki Y, Sato K, Matsuyama T. High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2019; 33:1906-1914. [PMID: 31323696 DOI: 10.1002/rcm.8531] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 07/01/2019] [Accepted: 07/12/2019] [Indexed: 06/10/2023]
Abstract
RATIONALE We developed a new high-throughput method to analyze tegafur (FT) and 5-fluorouracil (5-FU) in tear and plasma samples using hydrophilic interaction liquid chromatography (HILIC)/tandem mass spectrometry (MS/MS). METHODS The tear samples (10 μL) spiked with FT, 5-FU, and 5-chlorouracil (internal standard) were diluted using 40 μL of 2 M ammonium acetate and 250 μL of acetonitrile with 2% formic acid; 20 μL of plasma spiked with the two drugs and internal standard was diluted with 80 μL of 2 M ammonium acetate and 500 μL of acetonitrile with 2% formic acid. After centrifugation, the clear supernatant extract (15 μL) was directly injected into the HILIC/MS/MS instrument, and each drug was separated on a Unison UK-Amino column (50 mm × 3 mm i.d., 3 μm particle size) with a linear gradient elution system composed of 10 mM ammonium acetate (pH 6.8) and acetonitrile at a flow rate of 0.7 mL/min. We performed quantification by multiple reaction monitoring (MRM) with negative-ion atmospheric-pressure chemical ionization. RESULTS Distinct peaks were observed for the drugs on each MRM channel within 2 min. The regression equations showed good linearity within the range 0.04-4.0 μg/mL for the tear and plasma samples with detection limits at 0.02-0.04 μg/mL. Recoveries for target analytes (FT and 5-FU) for the tear and plasma samples were in the 94-128% and 94-104% ranges, respectively. The intra- and inter-day coefficients of variation for the two drugs were lower than 10.8%. The accuracies of quantitation were 97-115% for both samples. CONCLUSIONS We established a high-throughput, reproducible, and practical procedure for analyzing FT and 5-FU in human tear and plasma samples using HILIC/MS/MS analysis with an aminopropyl-bonded mixed-mode separation column. This method can be applied to the high-throughput routines used in clinical analyses.
Collapse
Affiliation(s)
- Ritsuko Shiokawa
- Department of Ophthalmology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
- Department of Legal Medicine, Showa University School of Medicine, Japan
| | - Xiao-Pen Lee
- Department of Legal Medicine, Showa University School of Medicine, Japan
| | - Miho Yamada
- Department of Ophthalmology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Masaya Fujishiro
- Department of Legal Medicine, Showa University School of Medicine, Japan
| | | | - Chika Hasegawa
- Department of Legal Medicine, Toho University School of Medicine, Japan
| | - Hiroo Ishida
- Division of Medical Oncology, Showa University School of Medicine, Japan
| | - Kenichiro Ikeda
- Department of Otorhinolaryngology, Showa University School of Medicine, Japan
| | - Ken-Ichi Fujita
- Department of Clinical Pharmacy, Showa University School of Medicine, Japan
| | - Shigehiro Iwabuchi
- Department of Ophthalmology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | - Hidetoshi Onda
- Department of Ophthalmology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
| | | | - Yasutsuna Sasaki
- Division of Medical Oncology, Showa University School of Medicine, Japan
| | - Keizo Sato
- Department of Legal Medicine, Showa University School of Medicine, Japan
| | - Takaaki Matsuyama
- Department of Legal Medicine, Showa University School of Medicine, Japan
| |
Collapse
|
30
|
Sasaki Y, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Miyagishima T, Hatanaka K, Dazai M, Ueda A, Sasaki T, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Hirose C, Iihara H, Funaguchi N, Endo J, Ito F, Yanase K, Kaito D, Sasaki Y, Gomyo T, Sakai C, Ohno Y, Suzuki A. Prophylactic effect of rikkunshito, an herbal medicine, for chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin-based chemotherapy. Pharmazie 2019; 74:620-624. [PMID: 31685089 DOI: 10.1691/ph.2019.9497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Rikkunshito has been shown to improve upper gastrointestinal symptoms and anorexia. The aim of this study was to evaluate whether rikkunshito improves chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin (CBDCA)-based chemotherapy. A retrospective before-and-after comparison study was conducted in patients with thoracic cancer receiving the first cycle of CBDCA-based chemotherapy. Among 61 eligible patients, 34 received standard antiemetic therapy with a combination of 5-hydroxytryptamine-3 receptor antagonist and dexamethasone from September 2012 and June 2013 (standard group), while the other 27 received the standard antiemetic therapy plus oral rikkunshito from July 2013 and December 2014 (rikkunshito group). The rates of no nausea showed no significant difference between the standard and rikkunshito group (Overall phase: 64.7 % for standard group vs 74.1 % for rikkunshito group, p = 0.579). Subgroup analysis indicated that, in female patients, the rates of no nausea in rikkunshito groups was significantly higher than in standard group (overall phase: 44.4 % vs 100 %, p = 0.034). Rikkunshito did not demonstrate an additional prophylactic effect on standard antiemetic therapy for nausea in patients with thoracic cancer receiving CBDCA-based chemotherapy, but showed a prophylactic effect of nausea in female patients.
Collapse
|
32
|
Kato J, Okuda J, Sasaki Y, Toya R, Morisaki H. Efficacy of jaw elevation device (JED®) for maintenance of upper airway patency during transcatheter aortic valve replacement under deep sedation. J Cardiothorac Vasc Anesth 2019. [DOI: 10.1053/j.jvca.2019.07.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
33
|
Matsumoto Y, Kabuki S, Sugawara A, Kitahara T, Akiba T, Fujita Y, Kawamata I, Yamada K, Amino K, Sasaki Y, Nishida M, Murakami K, Sugahara K, Saito N, Kunieda E. Basic evaluation of a novel 4D target and human body phantom. Phys Med Biol 2019; 64:145002. [PMID: 31146274 DOI: 10.1088/1361-6560/ab259c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Stereotactic body radiation therapy (SBRT) is usually verified with a dynamic phantom or solid phantom, but there is a demand for phantoms that can accurately simulate tumor dynamics within an individual that would allow customized validation in every patient. We developed a new 4D dynamic target phantom (multi-cell 4D phantom) that allows simulation of tumor movement in patients. The basic quality and dynamic reproducibility of this new phantom was verified in this investigation. The newly developed multi-cell 4D phantom comprises four main components: soft tissue, bones, lungs, and tumor (target). The phantom structure was based on computed tomography (CT) data of a male. In this study, we investigated the basic performance of a multi-cell 4D phantom. All the CT numbers of the phantom were very close to those of human data. The geometric maximum amplitudes were 4.57 mm in the lateral direction, 4.59 mm in the ventrodorsal direction, and 3.68 mm in the cranio-caudal direction. Geometric errors were 0.84, 0.58, and 0.40 mm, respectively. Movements of the abdominal surface were stable for 60 s. Repeated measurements show no actual differences in target movements between multiple measurements and indicated high reproducibility (r > 0.97). End-to-end tests using Gafchromic film revealed a gamma pass rate of 98% or above (2 mm/3%). Although our phantom performed limited reproducibility in the movement of the patient tumor at present, a satisfactory level of precision was confirmed in general. This is a very promising device for use in the verification of radiation therapy for moving targets.
Collapse
Affiliation(s)
- Y Matsumoto
- Department of Radiation Oncology, Tokai University Hachioji Hospital, Hachioji, Tokyo, 192-0032, Japan. Author to whom correspondence should be addressed
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Masuo Y, Kato Y, Sasaki Y. Abstract 3883: High unbound plasma concentration of M-2, an active metabolite, is associated with shorter survival in patients with metastatic colorectal cancer who received regorafenib. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Aims: Regorafenib is an oral multikinase inhibitor which showed survival advantage in the later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). This anticancer drug is sequentially metabolized to pharmacologically active metabolites M-2 and M-5 by the hepatic CYP3A. A randomized phase II trial has recently revealed that initial dose of 80 mg/day followed by dose escalations (40 mg/week) was superior to the standard dosing strategy (160 mg/day) with respect to overall survival (OS), resulting in the NCCN guideline recommendation for this dose escalation strategy, although scientific index for rational dose estimation is still limited. The aim of this prospective study was to clarify the association of pharmacokinetics (PK) with clinical outcome of regorafenib in patients with mCRC.
Methods: Consecutive patients with mCRC administered regorafenib at Showa University Hospital were prospectively enrolled in this study. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4 weeks cycle. Blood samples for PK analysis were obtained on day1 (0-48 h) skipping the second dose on day2, and if possible day15 of treatment (0-24 h). Plasma concentrations of the regorafenib, M-2, and M-5 were analyzed by HPLC or LC-MS/MS. Unbound fraction of these compounds were measured by equilibrium dialysis method.
Results: A total of 36 patients were enrolled between October 2013 and June 2017. The median progression free survival (PFS) was 1.9 months, and the median OS was 6.4 months. Area under the total (protein bound plus unbound) plasma concentration-time curve (AUC) on day1 was the highest in regorafenib (88.5 ± 53.8 µM·h), followed by M-2 and M-5 (37.0 ± 32.9 and 5.9 ± 6.5 µM·h, respectively), whereas AUC calculated based on unbound plasma concentration (uAUC) of M-2 was the highest (9.8 ± 12.0 nM·h), followed by M-5 and regorafenib (2.5 ± 4.3 and 1.8 ± 1.7 nM·h, respectively), reflecting ~10-fold higher unbound fraction in M-2 and M-5 than regorafenib. uAUC of M-2 measured on day15 was also higher than those of M-5 and regorafenib. Patients with the M-2 uAUC of 9.8 nM·h or higher had significantly shorter PFS than those with the uAUC of lower than 9.8 nM·h (30 vs. 74 days, p=0.0092). The highest uAUC value of M-2 may be compatible with its association with PFS, implying that unbound form of M-2 could be primarily important for clinical response.
Conclusion: We thus found that uAUC of active M-2 was the highest as compared to those of regorafenib and M-5, which was associated with shorter PFS.
Citation Format: Yutaro Kubota, Ken-ichi Fujita, Takehiro Takahashi, Yu Sunakawa, Hiroo Ishida, Kazuyuki Hamada, Wataru Ichikawa, Takuya Tsunoda, Yusuke Masuo, Yukio Kato, Yasutsuna Sasaki. High unbound plasma concentration of M-2, an active metabolite, is associated with shorter survival in patients with metastatic colorectal cancer who received regorafenib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3883.
Collapse
Affiliation(s)
| | | | | | - Yu Sunakawa
- 3St. Marianna University School of Medicine, Kanagawa, Japan
| | - Hiroo Ishida
- 1Showa University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
35
|
Ueda A, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Dazai M, Kawahata S, Sasaki T, Sasaki Y, Kato S, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Suzuki A, Sato H, Sasaki Y. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan? Clin Transl Sci 2019; 12:505-512. [PMID: 31062933 PMCID: PMC6742944 DOI: 10.1111/cts.12644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 04/06/2019] [Indexed: 12/26/2022] Open
Abstract
In Japan, the Pharmaceuticals and Medical Devices Agency requires all-case surveillance studies (ACSS) for many novel oncology drugs as a condition for approval. However, this is a major burden on the pharmaceutical industry and clinicians. The objective of this analysis was to investigate whether ACSS can contribute essential new information on severe adverse drug reactions, which are necessary to revise the package inserts of drugs. All oncology drugs for which ACSS were required from January 2006-September 2015 found on the Pharmaceuticals and Medical Devices Agency website were reviewed, and the influence of ACSS on the package insert content was evaluated. Most of the package insert revisions regarding serious treatment-related adverse events were based on spontaneous reports from clinicians. The contribution of ACSS results to the revision of package inserts is limited and comes at the cost of financial resources and labor. An alternative, more efficient adverse-event reporting system is necessary.
Collapse
Affiliation(s)
- Akiyuki Suzuki
- Division of Pharmacokinetics and Pharmacodynamics, Department of Drug Information, Showa University School of Pharmacy, Tokyo, Japan
| | - Hitoshi Sato
- Division of Pharmacokinetics and Pharmacodynamics, Department of Drug Information, Showa University School of Pharmacy, Tokyo, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.,Oncology Center, Musashino Tokushukai Hospital, Tokyo, Japan
| |
Collapse
|
37
|
Al-Shammari AH, Masuo Y, Fujita KI, Yoshikawa Y, Nakamichi N, Kubota Y, Sasaki Y, Kato Y. Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice. J Pharm Sci 2019; 108:2173-2179. [DOI: 10.1016/j.xphs.2019.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 01/15/2019] [Accepted: 01/17/2019] [Indexed: 02/07/2023]
|
38
|
Fujita T, Sakuragi M, Miyazaki C, Shiba S, Sasaki Y, Nishida S, Matsumiya M. Pregnancy-associated breast cancer: clinicopathologic and immunohistochemical features. Breast 2019. [DOI: 10.1016/s0960-9776(19)30442-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
39
|
Sasaki Y, Madada-Nyakauru RN, Samaras S, Oni G, Di Candia M, Malata CM. The ideal intercostal space for internal mammary vessel exposure during total rib-sparing microvascular breast reconstruction: A critical evaluation. J Plast Reconstr Aesthet Surg 2019; 72:1000-1006. [PMID: 30824382 DOI: 10.1016/j.bjps.2019.01.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 12/27/2018] [Accepted: 01/06/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Total rib-preserving free flap breast reconstruction (RP-FFBR) using internal mammary vessel (IMV) recipients usually involves vessel exposure in the second or third intercostal spaces (ICS). Although the third one is more commonly used, no direct comparisons between the two have hitherto been performed. OBJECTIVES To compare the in-vivo topography and vascular anatomy of second and third ICSs in patients undergoing FFBR using the rib-preservation technique of IMV exposure. METHODS An analysis of prospectively collected data on intercostal space distance (ISD), number and arrangement of IMVs, location of venous confluence, and vessel exposure time was conducted on a single surgeon's consecutive RP-FFBRs. RESULTS A total of 296 RP-FFBRs were performed in 246 consecutive patients. The second, third, or both second and third spaces were utilized in 282, 28, and 22 cases, respectively. The ISDs were 20.6 mm ± 3.52 for the second ICS and 14.0 mm ± 4.35 for the third ICS (p<0.0001, CI = 5.17-7.97, t-test). The second versus third ICS vein content was as follows: single 81.4% vs. 74%, dual 18.6% vs. 26%, and confluence 3.7% vs. 13%. The second ICS single vein was medial to the artery in 92.6%. The third ICS single vein was medial to the artery in 88.2% Vessel exposure times for second (47.2 mins ± 26.7) and third (46.5 mins ± 31.4) spaces were similar (p = 0.93). The overall intraoperative anastomotic revision rate was 9.1%, and the postoperative flap re-exploration rate was 4.0%, with 99.7% overall flap success. DISCUSSION AND CONCLUSION Preferential use of the second ICS is supported by its more predictable vascular anatomy, a broader space for performing the microanastomoses and a higher frequency of a single postconfluence (and thus larger) vein facilitating the microsurgery.
Collapse
Affiliation(s)
- Y Sasaki
- Department of Plastic Surgery, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
| | - R N Madada-Nyakauru
- Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK
| | - S Samaras
- Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK
| | - G Oni
- Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK
| | - M Di Candia
- Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK; University Department of Plastic Surgery, University di Bari, Piazza Giulio Cesare, 11, 70124 Bari, Italy
| | - C M Malata
- Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK; Anglia Ruskin University School of Medicine, Cambridge and Chelmsford, East Road, Cambridge, UK.
| |
Collapse
|
40
|
Katov Y, Hasan A, Masuo Y, Fujita KI, Kubota Y, Sasaki Y. ABC xenobiotic transporters play important roles in systemic exposure and dermal distribution of tyrosine kinase inhibitor regorafenib and its active metabolites. Drug Metab Pharmacokinet 2019. [DOI: 10.1016/j.dmpk.2018.09.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Yamauchi R, Maguin E, Horiuchi H, Hosokawa M, Sasaki Y. The critical role of urease in yogurt fermentation with various combinations of Streptococcus thermophilus and Lactobacillus delbrueckii ssp. bulgaricus. J Dairy Sci 2018; 102:1033-1043. [PMID: 30594386 DOI: 10.3168/jds.2018-15192] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 09/18/2018] [Indexed: 11/19/2022]
Abstract
The protocooperation between Streptococcus thermophilus and Lactobacillus delbrueckii ssp. bulgaricus relies on metabolite exchanges that accelerate acidification during yogurt fermentation. Conflicting results have been obtained in terms of the effect of the Strep. thermophilus urease and the NH3 and CO2 that it generates on the rate of acidification in yogurt fermentation. It is difficult to perform a systematic study of the effects of urease on protocooperation because it is necessary to distinguish among the direct, indirect, and strain-specific effects resulting from the combination of the strains of both species. To evaluate the direct effects of urease on protocooperation, we generated 3 urease-deficient mutants (ΔureC) of fast- and slow-acidifying Strep. thermophilus strains and observed the effects of NH3 or CO2 supplementation on acidification by the ΔureC strains. Further, we examined 5 combinations of 3 urease-deficient ΔureC strains with 2 CO2-responsive or CO2-unresponsive strains of L. bulgaricus. Urease deficiency induced a shortage of ammonia nitrogen and CO2 for the fast- and slow-acidifying Strep. thermophilus and for the CO2-responsive L. bulgaricus, respectively. Notably, the shortage of ammonia nitrogen had more severe effects than that of CO2 on yogurt fermentation, even if coculture with L. bulgaricus masked the effect of urease deficiency. Our work established (1) that urease deficiency inhibits the fermentative acceleration of protocooperation regardless of the Strep. thermophilus and L. bulgaricus strain combinations, and (2) that urease is an essential factor for effective yogurt acidification.
Collapse
Affiliation(s)
- R Yamauchi
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan.
| | - E Maguin
- INRA UMR1319 Micalis Allée de Vilvert Bat. 440, R-1, Pce 420, 78352 Jouy-en-Josas Cedex, Ile de France, France
| | - H Horiuchi
- Food Development Laboratories, R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachioji, Tokyo 192-0919, Japan
| | - M Hosokawa
- Chuo University of Junior and High School, 3-22-1 Nukuikitamachi, Koganei, Tokyo, 184-8575, Japan
| | - Y Sasaki
- Graduate School of Agriculture, University of Meiji, 1-1-1 Higashi-Mita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan
| |
Collapse
|
42
|
Satoh E, Sasaki Y, Ohkuma R, Takahashi T, Kubota Y, Ishida H, Hamada K, Kiuchi Y, Tsunoda T. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan. Cancer Sci 2018; 109:3896-3901. [PMID: 30315613 PMCID: PMC6272097 DOI: 10.1111/cas.13831] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Revised: 07/12/2018] [Accepted: 07/23/2018] [Indexed: 02/01/2023] Open
Abstract
Both overall survival (OS) and progression-free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the relationship between oncology drug prices and clinical outcomes in Japan. The costs of a full course or 1 year of treatment were estimated on the basis of the latest National Health Insurance Drug Price Standards, and the relationship between costs and improvements in OS or PFS obtained with each drug were analyzed. Cost-effectiveness was compared between new-class drugs and next-in-class drugs. We then developed a simple model for estimating the costs required to prolong OS and PFS by 1 day and used this model to compare cost-effectiveness. Drug costs were not significantly related to treatment outcomes in terms of PFS or OS. There was no significant difference in the median cost between novel drugs and the next-in-class drugs (P = 0.39). The oncology drug cost required to prolong PFS by 1 day was more expensive than the drug cost required for prolong OS by 1 day. Prices of oncology drugs should be decided on the basis of actual clinical benefits for cancer patients, and the drug price evaluation process should be disclosed in Japan.
Collapse
Affiliation(s)
- Etsuko Satoh
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ryotaro Ohkuma
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Takehiro Takahashi
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yutaro Kubota
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hiroo Ishida
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Kazuyuki Hamada
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yuji Kiuchi
- Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan
| | - Takuya Tsunoda
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
43
|
Abstract
Context and Aims Japanese cuisine is now popular worldwide, and consumption of raw fish has thus increased at sushi bars and Japanese restaurants outside Japan. Anisakiasis, also known as herring-worm disease, is caused by ingesting larval nematodes in raw seafood and is a common illness in Japan. However, due to the rising popularity of Japanese food, gastroenterologists outside Japan need to be familiar with this disease. Subjects and Methods and Results We treated 158 patients presenting with acute gastrointestinal manifestations caused by anisakiasis from April 1991 to April 2000. One or more nematodes were removed endoscopically within 48 h of presentation in 44% of these patients, which resulted in prompt resolution of symptoms. Major endoscopic findings were gastric ulcer accompanied by hemorrhage, erosion, redness, and edema of the gastric mucosa in areas penetrated by larvae and other areas. Conclusions Endoscopy was valuable for the diagnosis and treatment of anisakiasis. We recommend endoscopy in suspected cases of anisakiasis. Moreover, it is desirable to combine complementary tests such as immunological tests/IgE measurement. As the popularity of Japanese cuisine increases, reports of anisakiasis are likely to be more frequent in countries other than Japan.
Collapse
Affiliation(s)
- K Furuya
- Department of General Medicine and Emergency Care, School of Medicine, Omori Hospital, Toho University, Tokyo, Japan
| | - H Nakajima
- Department of Internal Medicine, Kizukuri Adult Disease Center, Aomori, Japan
| | - Y Sasaki
- Department of General Medicine and Emergency Care, School of Medicine, Omori Hospital, Toho University, Tokyo, Japan
| | - Y Urita
- Department of General Medicine and Emergency Care, School of Medicine, Omori Hospital, Toho University, Tokyo, Japan
| |
Collapse
|
44
|
Tsuboya A, Fujita KI, Kubota Y, Ishida H, Taki-Takemoto I, Kamei D, Iwai S, Sasaki Y. Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer. Int J Clin Oncol 2018; 24:222-230. [DOI: 10.1007/s10147-018-1347-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 09/16/2018] [Indexed: 12/01/2022]
|
45
|
Adachi Y, Akino K, Nojima M, Himori R, Kikuchi T, Mita H, Nakamura M, Tsukuda H, Yamano HO, Sasaki Y, Yoshida Y, Kato Y, Nakase H, Endo T. Prognostic nutritional index and early mortality with percutaneous endoscopic gastrostomy. QJM 2018; 111:635-641. [PMID: 29939360 DOI: 10.1093/qjmed/hcy137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Although percutaneous endoscopic gastrostomy (PEG) is a well-accepted and less invasive method of feeding tube placement in patients with swallowing difficulties, complications and early death after PEG have been reported. AIM This study aimed to evaluate predictive factors associated with 30-day mortality after PEG, and to assess the utility of nutritional supporting period before PEG in reducing early mortality following PEG. DESIGN An observational study. METHODS We retrospectively analyzed 268 patients who underwent PEG at Sapporo Shirakaba-dai Hospital from 2006 to 2010, using clinical and laboratory data to analyze predictive factors associated with early death after PEG. Then, we prospectively assessed 152 consecutive patients assessed for eligibility for PEG from 2011 to 2014. We assessed the patients' nutritional condition using Onodera's prognostic nutritional index (PNI), and supported nutrition for more than 10 days before PEG in patients with a poor nutritional index (PNI < 37). RESULTS In both univariate and multivariate analyses in the retrospective study, Onodera's PNI of less than 37 was the only predictive factor for early mortality. In the second study, among the 115 patients who finally underwent PEG, early mortality rates improved to 1.7% from 5.2% in the first study. Conversely, 32% of patients with malnutrition who did not undergo PEG died within 30 days. CONCLUSION Nutritional status might be a predictive factor for early mortality after PEG. In patients with poor nutritional status, nutritional supporting period before PEG might improve the outcomes and reduce unnecessary PEG.
Collapse
Affiliation(s)
- Y Adachi
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - K Akino
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - M Nojima
- Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
| | - R Himori
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - T Kikuchi
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Mita
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - M Nakamura
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Tsukuda
- Department of Internal Medicine, Sapporo Shirakaba-dai Minami Hospital, Sapporo, Japan
| | - H-O Yamano
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - Y Sasaki
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - Y Yoshida
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - Y Kato
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Nakase
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - T Endo
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| |
Collapse
|
46
|
Affiliation(s)
- Kazuyuki Hamada
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yasutsuna Sasaki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Japan
| |
Collapse
|
47
|
Azumi Y, Tani T, Ishibashi K, Konda T, Sumida T, Sasaki Y, Ota M, Kim K, Kitai T, Yamane T, Kobori A, Ehara N, Kinoshita M, Kaji S, Furukawa Y. 1470Impact of left atrial enlargement on very long-term outcomes in patients with hypertrophic cardiomyopathy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Azumi
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Tani
- Kobe City College of Nursing, kobe, Japan
| | - K Ishibashi
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Konda
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Sumida
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - M Ota
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - K Kim
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Yamane
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - N Ehara
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - M Kinoshita
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - S Kaji
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| |
Collapse
|
48
|
Matsumoto Y, Kobori A, Sasaki Y, Furukawa Y. P998Assessment of adenosine triphosphate test and necessity of additional gap ablation after cryoballoon pulmonary vein isolation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Matsumoto
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Kobe, Japan
| |
Collapse
|
49
|
Ota M, Kitai T, Horita R, Azumi Y, Matsumoto Y, Ishizu K, Sasaki Y, Kim K, Yamane T, Kobori A, Ehara N, Kinoshita M, Kaji S, Furukawa Y. P3418A detailed assessment of geometric height of normal aortic cusps by 3-dimensional transesophageal echocardiography: implications for aortic valve repair surgery. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Ota
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - R Horita
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Azumi
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Matsumoto
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - K Ishizu
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Sasaki
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - K Kim
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - T Yamane
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - A Kobori
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - N Ehara
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - M Kinoshita
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - S Kaji
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| | - Y Furukawa
- Kobe City Medical Center General Hospital, Cardiovascular Medicine, Kobe, Japan
| |
Collapse
|
50
|
Sasaki Y, Hirota J, Konno J. The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|